Early Temporal Dissociation Between C-Reactive Protein and Neutrophil Counts After Spesolimab Treatment in Generalized Pustular Psoriasis

Authors

  • Ayu Watanabe Department of Dermatology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
  • Masahiro Kamata Department of Dermatology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan https://orcid.org/0000-0003-0976-4982
  • Yoshiki Okada Department of Dermatology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
  • Kotaro Hayashi Department of Dermatology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
  • Yayoi Tada Department of Dermatology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan

DOI:

https://doi.org/10.2340/actadv.v106.adv-2026-0804

Keywords:

generalized pustular psoriasis, spesolimab, interleukin-36 receptor, systemic inflammation, C-reactive protein

Downloads

Download data is not yet available.

References

Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med 2021; 385: 2431–2440. DOI: https://doi.org/10.1056/NEJMoa2111563

Okada Y, Kamata M, Hayashi K, Sugiura K, Tada Y. Effectiveness and safety of spesolimab in patients with generalized pustular psoriasis: a single-centre retrospective study. Acta Derm Venereol 2025; 105: adv42879. DOI: https://doi.org/10.2340/actadv.v105.42879

Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol 2018; 45: 1235–1270. DOI: https://doi.org/10.1111/1346-8138.14523

Farag A, Visvanathan S, Bachelez H, Morita A, Lebwohl MG, Barker JN, et al. Spesolimab reduces inflammation in generalized pustular psoriasis: molecular characterization of flare treatment in EFFISAYIL 1. J Invest Dermatol 2025; 145: 573–582. DOI: https://doi.org/10.1016/j.jid.2024.05.034

Ito M, Kamata M, Uchida H, Egawa S, Nagata M, Fukaya S, et al. Ixekizumab rapidly improves inflammatory markers in patients with generalized pustular psoriasis. Br J Dermatol 2022; 187: 793–795. DOI: https://doi.org/10.1111/bjd.21701

Uchida H, Kamata M, Egawa S, Nagata M, Fukaya S, Hayashi K, et al. A real-world, single-center experience and the immediate impact of granulocyte and monocyte adsorption apheresis on generalized pustular psoriasis. J Am Acad Dermatol 2022; 87: 1181–1184. DOI: https://doi.org/10.1016/j.jaad.2022.03.001

Downloads

Published

2026-08-25

How to Cite

Watanabe, A., Kamata, M., Okada, Y., Hayashi, K., & Tada, Y. (2026). Early Temporal Dissociation Between C-Reactive Protein and Neutrophil Counts After Spesolimab Treatment in Generalized Pustular Psoriasis. Acta Dermato-Venereologica, 106, adv–2026. https://doi.org/10.2340/actadv.v106.adv-2026-0804

Issue

Vol. 106 (2026)

Section

Short Communication

Categories

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC